Substantial Declines in Mortality Rates for Most Cancers

According to a new analysis, cancer-related mortality rates have fallen substantially over the past 50 years.
Researchers found that total mortality rates from all cancers fell by 27% overall between 1971 and 2019. This decline was evident in 12 of the 15 cancer types analyzed. The data come from US cancer statistics.
The findings showed that mortality rates for certain cancers in particular years were even higher. For example, deaths from lung cancer were 44% lower in 2019 than at the peak rate in 1993.
The study’s lead author, Dr. Ahmedin Jemal, said, "The overall cancer death rate has declined substantially since 1971, as have rates for most cancer sites, because of advances in cancer protection/prevention, early diagnosis, and treatment". In other words, this progress came from both increased early diagnosis and new treatments such as targeted drugs and immunotherapies.
Jemal and colleagues explained that advances over the past five decades in surgery, radiotherapy, chemotherapy, precision medicine, and combination therapies contributed to these substantial declines in mortality (death rates).
Another notable point is cancer spending: in the USA alone, the cancer budget rose from 227 million dollars in 1971 to 6 billion dollars in 2019, a 25-fold increase.
JAMA Oncology published an online report that analyzed mortality rates for all cancers and the 15 most common cancer types recorded by the US National Center for Health Statistics.
Researchers found that overall deaths from all cancers fell substantially during the study period. Since 1971, the greatest improvements in cancer mortality were observed for stomach and cervical cancers: declines of 72% and 69%, respectively. These were followed by colorectal cancers (56%), oral cavity and pharyngeal cancer (43%), and ovarian cancer (41%). Breast and prostate cancer death rates also fell substantially - both by 39%.

Jemal and colleagues said, "The decline in mortality from breast, cervical, colorectal, and prostate cancers partly reflects increased detection (and removal) of early-stage cancers".
The Contribution of Chemotherapy
Adjuvant (postoperative preventive) chemotherapy accounted for 63% of the decline in female breast cancer deaths between 2000 and 2012.
The authors also note that "declines in lung, oral cavity, and bladder cancers largely reflect reduced smoking because of increased public awareness of its health consequences, higher tobacco excise taxes, and comprehensive smoke-free laws".
However, mortality rates did not improve significantly in several categories. Pancreatic and esophageal cancer were given as examples. Nevertheless, immunotherapy approvals providing significant survival improvements in esophageal cancer have arrived in the past two years; we will see the long-term statistical outcomes of these new treatments in the coming years.
The authors suggested that the unfavorable situation in pancreatic cancer probably reflects rising obesity rates and a lack of significant progress in pancreatic cancer prevention, early diagnosis, or treatment.
In conclusion, improving equity through investment in the social determinants of health and implementation research is critical to advancing the national cancer control agenda.
Sources
2. Tyler B. Kratzer, MPH; Rebecca L. Siegel, MPH; Kimberly D. Miller, MPH; et al. Progress Against Cancer Mortality 50 Years After Passage of the National Cancer Act. JAMA Oncology 11 Nov 2021
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.